SCHEMBL5654906

SCHEMBL5654906

CCOC(=O)Cc1ccc2oc(=O)[nH]c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 4/20 0.51
NOS3 P29474 3/20 0.51
NOS2 P35228 3/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
LMNA P02545 2/20 0.44
CYP1A2 P05177 1/20 0.44
ADRA2A P08913 1/20 0.44
TSHR P16473 1/20 0.44
THPO P40225 1/20 0.44
BLM P54132 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PDE10A Q9Y233 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 1/20 0.42
CREBBP Q92793 1/20 0.41
HCAR2 Q8TDS4 1/20 0.41
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29749857 0.86 NOS3 (0.50) NOS1NOS3NOS2MEN1KMT2A
SCHEMBL15270401 0.86 NOS3 (0.50) NOS1NOS3NOS2MEN1KMT2A
SCHEMBL12095295 0.81 NOS1 (0.54) NOS1NOS3NOS2MEN1KMT2A
SCHEMBL9131214 0.80 NOS1 (0.51) NOS1NOS3NOS2MEN1KMT2A
SCHEMBL7903542 0.78 NOS1 (0.61) NOS1NOS3NOS2MEN1KMT2A
SCHEMBL6763567 0.77 SMN1; SMN2 (0.54) MEN1KMT2ASMN1; SMN2POLBHCAR2
SCHEMBL22057895 0.76 PDE3B (0.51) NOS1LMNATSHRCREBBPPDE3B
SCHEMBL2940114 0.75 NOS1 (0.56) NOS1NOS3NOS2MEN1KMT2A
SCHEMBL16729160 0.73 ALOX15 (0.52) MEN1KMT2ATSHRSMN1; SMN2POLB
SCHEMBL16413069 0.73 SMN1; SMN2 (0.50) MEN1KMT2ALMNASMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7186730-B2 Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2007-03-06 US disclosed
EP-1392686-B1 BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2006-10-18 EP disclosed
US-20040198755-A1 Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2004-10-07 US disclosed
EP-1392686-A1 BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2004-03-03 EP disclosed
WO-2002096907-A1 BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM P.L.C. (GB) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198755-A1 Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials NRDC, NUCB2, ASNS NOS1 161/4885NOS3 178/4885NOS2 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.